CAPNS1 and cancer: Overall, Capn4 exhibited the powerful clinical usefulness of Capn4 as a promising biomarker in cancer survivors, and the results of this cumulative meta-analysis provided a clue toward understanding the potential clinical utility of Capn4 as an unfavorable predictor as well as a new therapeutic target in cancers.